Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment

0 Views
administrator
administrator
07/06/23

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.

Show more

0 Comments Sort By

No comments found

Facebook Comments

Up next